Skip to main content

Subcutaneous Fat

9
Pipeline Programs
2
Companies
11
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
6
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Caliway Biopharmaceuticals
Caliway BiopharmaceuticalsTaiwan - New Taipei City
9 programs
1
6
2
CBL-514 InjectionPhase 31 trial
CBL-514 InjectionPhase 31 trial
CBL-514Phase 21 trial
CBL-514Phase 21 trial
CBL-514Phase 21 trial
+4 more programs
Active Trials
NCT04699669Completed40Est. Aug 2019
NCT04698642Completed43Est. Nov 2020
NCT04575467Completed25Est. Dec 2021
+6 more trials
AbbVie
AbbVieNORTH CHICAGO, IL
2 programs
Deoxycholic acid InjectionN/A1 trial
ZELTIQ thermoelectric deviceN/A1 trial
Active Trials
NCT03682471Completed201Est. Dec 2013
NCT04553627Unknown10Est. May 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Caliway BiopharmaceuticalsCBL-514 Injection
Caliway BiopharmaceuticalsCBL-514 Injection
Caliway BiopharmaceuticalsCBL-514 injection
Caliway BiopharmaceuticalsCBL-514 Injection
Caliway BiopharmaceuticalsCBL-514 Injection
Caliway BiopharmaceuticalsCBL-514
Caliway BiopharmaceuticalsCBL-514
Caliway BiopharmaceuticalsCBL-514
Caliway BiopharmaceuticalsCBL-514, placebo
AbbVieZELTIQ thermoelectric device
AbbVieDeoxycholic acid Injection

Clinical Trials (11)

Total enrollment: 1,304 patients across 11 trials

A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 )

Start: Oct 2026Est. completion: Oct 2027320 patients
Phase 3Not Yet Recruiting

A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat

Start: Jul 2026Est. completion: Jul 2027300 patients
Phase 3Not Yet Recruiting

A Phase 2b Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat.

Start: Nov 2023Est. completion: Oct 2024173 patients
Phase 2Completed

A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat

Start: May 2023Est. completion: May 2024107 patients
Phase 2Completed

A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2)

Start: Feb 2022Est. completion: Mar 202375 patients
Phase 2Completed

A Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy Volunteers

Start: Feb 2022Est. completion: Jun 202210 patients
Phase 2Completed

A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)

Start: Dec 2020Est. completion: Dec 202125 patients
Phase 2Completed

A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CBL-514 Injection for Reducing Convexity or Fullness of Abdominal Subcutaneous Fat

Start: Feb 2020Est. completion: Nov 202043 patients
Phase 2Completed

A Phase 1 Study to Evaluate the Safety and Tolerability of CBL-514 Injection on Convexity or Fullness of Abdominal Subcutaneous Fat in Healthy Volunteers

Start: Nov 2018Est. completion: Aug 201940 patients
Phase 1Completed
NCT04553627AbbVieZELTIQ thermoelectric device

Feasibility of Producing the Appearance of a Gluteal Lift Post Cryolipolysis

Start: Jul 2020Est. completion: May 202110 patients
N/AUnknown
NCT03682471AbbVieDeoxycholic acid Injection

Long-term 24-month Follow-up Study on Safety and Maintenance of Efficacy of ATX-101 (Sodium Deoxycholate Injection)

Start: Feb 2012Est. completion: Dec 2013201 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.